ReviewF1000Research2018
Research and development of new tuberculosis vaccines: a review.
Review in F1000Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.PloS one · 2019Trial
- Article
- Development of a Vaccine Candidate Based on Surface-Displayed Particles ofInternational journal of molecular sciences · 2025Article
- A broader lens on tuberculosis cost-effectiveness analysis: How patient-incurred costs and post-tuberculosis outcomes reshape estimates in a multi-country study.PLOS global public health · 2025Article
- Therapeutic vaccination with the Ag85B-Rv2660c-MPT70 fusion protein enhancesFrontiers in immunology · 2025Article
- A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy.PLoS biology · 2024Article
- Application of CRISPR-cas-based technology for the identification of tuberculosis, drug discovery and vaccine development.Molecular biology reports · 2024Review
- Addressing mechanism bias in model-based impact forecasts of new tuberculosis vaccines.Nature communications · 2023Article
- Is neglect of self-clearance biasing TB vaccine impact estimates?BMJ global health · 2023Article
- RNA Microarray-Based Comparison of Innate Immune Phenotypes between Human THP-1 Macrophages Stimulated with Two BCG Strains.International journal of molecular sciences · 2022Article
- Accelerating research and development of new vaccines against tuberculosis: a global roadmap.The Lancet. Infectious diseases · 2022Review
- Photochemically-Mediated Inflammation and Cross-Presentation ofFrontiers in immunology · 2022Article
- It Takes a Village: The Multifaceted Immune Response toFrontiers in immunology · 2022Review
- PE_PGRS33, an Important Virulence Factor ofCells · 2021Review
- New Developments and Insights in the Improvement ofCurrent epidemiology reports · 2021Review
- Recent Advances in the Development of Protein- and Peptide-Based Subunit Vaccines against Tuberculosis.Cells · 2020Review
- Diagnostic Potential of a PPE Protein Derived fromYonsei medical journal · 2020Article
- 6,6'-Aryl trehalose analogs as potential Mincle ligands.Bioorganic & medicinal chemistry · 2020Article
- Development of a TB vaccine trial site in Africa and lessons from the Ebola experience.BMC public health · 2020Article
- Integrating Biomaterials and Immunology to Improve Vaccines Against Infectious Diseases.ACS biomaterials science & engineering · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Tuberculosis kills more people worldwide than any other single infectious disease agent, a threat made more dire by the spread of drug-resistant strains of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.